PD-L1 Expression Guidance on Sintilimab Versus Pembrolizumab with or Without Platinum-Doublet Chemotherapy in Untreated Patients with Advanced Non-Small Cell Lung Cancer (CTONG1901): A Phase 2, Randomized, Controlled Trial.
SCIENCE BULLETIN（2024）
Key words
PD-1 inhibitor,Non-small cell lung cancer,Pembrolizumab,Sintilimab,PD-L1 expression
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined